澳大利亚批准新的氯胺酮鼻腔喷剂Spravato,用于几十年后的严重抑郁。 Australia approves new ketamine-based nasal spray, Spravato, for severe depression after decades.

澳大利亚政府批准了Spravato, 一种抗治疗抗抑郁的氯胺酮类鼻涕喷雾, 标志着三十年来政府支持的首次心理健康新倡议。 The Australian government has approved Spravato, a ketamine-like nasal spray for treatment-resistant depression, marking the first new government-backed mental health initiative in three decades. Spravato 以谷氨酸（一种神经递质）为靶点，在对常规治疗没有反应的患者中，约有 50% 的患者显示出显著改善。 Spravato targets glutamate, a neurotransmitter, and has shown significant improvement in about 50% of patients who did not respond to conventional treatments. 通过药品福利计划,大多数澳大利亚人每剂药物费用为31.60美元,养恤金领取者和特许卡持有者每剂药品费用为7.70美元,加上额外的保健费用。 Available through the Pharmaceutical Benefits Scheme, the drug costs $31.60 per dose for most Australians and $7.70 for pensioners and concession cardholders, with additional healthcare costs.